Cargando…

Multidisciplinary supportive care in systemic light chain amyloidosis

The immunoglobulin light-chain amyloidosis is a multisystemic disease which manifests by damage to the vital organs by light chain-derived amyloid fibril. Traditionally, the treatment has been directed to the underlying plasma cell clone with or without high dose chemotherapy followed by autologous...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maroun, Bou Zerdan, Allam, Sabine, Chaulagain, Chakra P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242830/ https://www.ncbi.nlm.nih.gov/pubmed/35593003 http://dx.doi.org/10.5045/br.2022.2021227

Ejemplares similares

Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia)
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Systemic AL amyloidosis: current approach and future direction
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

Recent Advances in the Treatment and Supportive Care of POEMS Syndrome
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Addendum: Systemic AL amyloidosis: current approach and future direction
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

A Synopsis Clonal Hematopoiesis of Indeterminate Potential in Hematology
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Challenges of Managing Multiple Myeloma Patients with Sickle Cell Disease: A Case Report and Review of Literature
por: Zerdan, Maroun Bou, et al.
Publicado: (2021)

Liquid biopsies and minimal residual disease in lymphoid malignancies
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

Adhesion molecules in multiple myeloma oncogenesis and targeted therapy
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Liquid biopsies and minimal residual disease in myeloid malignancies
por: Allam, Sabine, et al.
Publicado: (2023)

Metabolic Syndrome: Updates on Pathophysiology and Management in 2021
por: Fahed, Gracia, et al.
Publicado: (2022)

Predictors of Hospitalizations and Death from COVID-19 in Patients with Multiple Myeloma
por: Chaulagain, Chakra P, et al.
Publicado: (2022)

Single Cell RNA Sequencing: A New Frontier in Pancreatic Ductal Adenocarcinoma
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Carbapenemase Inhibitors: Updates on Developments in 2021
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Role of circulating tumor DNA and circulating tumor cells in breast cancer: History and updates
por: Chedid, Julien, et al.
Publicado: (2022)

Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2018)

Novel Therapies in Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2017)

Supportive Care and Symptom Management for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
por: Jensen, Christopher E., et al.
Publicado: (2022)

The Urogenital System’s Role in Diseases: A Synopsis
por: Zerdan, Maroun Bou, et al.
Publicado: (2022)

Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication
por: Baker, Kelty R.
Publicado: (2022)

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
por: Palladini, Giovanni, et al.
Publicado: (2021)

Insights of Medical Students and Graduates Toward Electronic Learning During the COVID-19 Pandemic in Lebanon: A National Cross-Sectional Study
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

Multidisciplinary Approaches for Transthyretin Amyloidosis
por: Koike, Haruki, et al.
Publicado: (2021)

Physiology, Diagnosis and Treatment of Cardiac Light Chain Amyloidosis
por: Stelmach-Gołdyś, Agnieszka, et al.
Publicado: (2022)

Light chain (AL) amyloidosis: update on diagnosis and management
por: Rosenzweig, Michael, et al.
Publicado: (2011)

Oligodendroglioma: A Review of Management and Pathways
por: Bou Zerdan, Maroun, et al.
Publicado: (2021)

Mechanisms of Immunotoxicity: Stressors and Evaluators
por: Bou Zerdan, Maroun, et al.
Publicado: (2021)

Microbial Influences on Immune Checkpoint Inhibitor Response in Melanoma: The Interplay between Skin and Gut Microbiota
por: Bouferraa, Youssef, et al.
Publicado: (2023)

T1 mapping and survival in systemic light-chain amyloidosis
por: Banypersad, Sanjay M., et al.
Publicado: (2015)

Systemic Light Chain Amyloidosis Mimicking Rheumatic Disorders
por: Rao, Rohit R., et al.
Publicado: (2016)

DUAL expectations in light chain amyloidosis
por: Schönland, Stefan, et al.
Publicado: (2020)

COVID-19 and Light Chain Amyloidosis, Adding Insult to Injury
por: Crees, Zachary D., et al.
Publicado: (2022)

Recent advances in understanding and treating immunoglobulin light chain amyloidosis
por: Badar, Talha, et al.
Publicado: (2018)

Immunoglobulin Light-Chain Amyloidosis: Clinical Presentations and Diagnostic Approach
por: Hwa, Yi L., et al.
Publicado: (2019)

Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis
por: Zhang, Kathleen W., et al.
Publicado: (2019)

The Lung Microbiota and Lung Cancer: A Growing Relationship
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives
por: Sarosiek, Shayna, et al.
Publicado: (2019)

Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics
por: Rognoni, Paola, et al.
Publicado: (2021)

Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021
por: Hasib Sidiqi, M., et al.
Publicado: (2021)

Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy
por: Chitimus, Diana Maria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3i7a8nuuvq2hpcbnhgami4m3p0